After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that Teva Reports Growth in Fourth Quarter and Full Year 2023.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
The company is listed on the NYSE and operates within the Drug Manufacturers – Specialty & Generic industry segment. At the end of the last regular session, the stock closed at $13.02 and fluctuated between $13.24 as its day high and $13.00 as its day low. The current market capitalization of Teva- Pharmaceutical Industries Ltd. ADR is $14.59B. A total of 5.65 million shares were traded on the day, compared to an average of 10.35M shares.
Insider Activity
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, TEVA has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 2 SELLs from insiders. Insiders purchased 0 shares during that period but sold 77,421.
In the most recent transaction, Weiss Amir sold 31,766 shares of TEVA for 12.37 per share on Feb 01. After the transaction, the Chief Accounting Officer now owns 10,676 company shares. In a previous transaction on Aug 07, Kalif Eliyahu Sharon sold 35,125 shares at 9.73 per share. TEVA shares that EVP, Chief Financial Officer owns now total 99,162.
Among the insiders who sold shares, Weiss Amir disposed of 1,981 shares on Aug 04 at a per-share price of $9.92. This resulted in the Chief Accounting Officer holding 42,442 shares of TEVA after the transaction. In another insider transaction, Hughes Eric A sold 52,742 shares at $8.30 per share on Aug 01. Company shares held by the See “Remarks” now total 0.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for TEVA in the last 3 months, the mean price target is $14.88 with high estimates of $19.00 and low estimates of $11.00. In terms of 52-week highs and lows, TEVA has a high of $13.35 and a low of $7.09.
As of this writing, TEVA has an earnings estimate of $Enviva Inc. per share for the current quarter. EPS was calculated based on a consensus of Teva Pharmaceutical Industries estimates, with a high estimate of $Aeva Technologies, Inc. per share and a lower estimate of $CEVA, Inc.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. TEVA’s latest balance sheet shows that the firm has $2.17B in Cash & Short Term Investments as of fiscal 2021. There were $23.46B in debt and $11.03B in liabilities at the time. Its Book Value Per Share was $6.70, while its Total Shareholder’s Equity was $11.24B.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TEVA is Buy with a score of 4.11.
